BioAffinity’s CyPath Lung Test unit sales surged 146% y/y in Q1

bioAffinity Technologies (BIAF) announced that unit sales for its CyPath Lung diagnostic in the first quarter of 2026 exceeded internal projections and, based on preliminary unaudited data, achieved 146% growth compared to the first quarter of 2025, reflecting accelerating physician adoption and expanding clinical use of the Company’s noninvasive lung cancer diagnostic test. “The stronger than expected unit growth in the first quarter of 2026 reflects growing recognition of the value that CyPath(R) Lung brings to clinical decision-making and patient outcomes,” said Maria Zannes, President and CEO of bioAffinity Technologies. “Physicians are seeking more accurate, noninvasive tools to assess lung cancer risk and detect disease at its earliest, most treatable stage. CyPath(R) Lung is designed to address a critical gap in the diagnostic pathway by supporting lung cancer risk assessment, pulmonary nodule management and post-treatment surveillance. Our growing body of evidence – including real-world case studies – further supports CyPath(R) Lung’s potential clinical utility.”